Congenital afibrinogenaemia and successful pregnancy outcome. Case report

Trehan, Amita; Fergusson, I. L. C.

doi:10.1111/j.1471-0528.1991.tb13464.x

Cited by 38 publications

(31 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 -20 From a total five deliveries in four women, three cesarean deliveries have been reported with Fg replacement therapy, 24 -26 and two vaginal deliveries were experienced with similar treatment. 26,27 We found the same general situation to exist in our mouse model of a total Fg deficiency. In cases of pregnancies of FG Ϫ/Ϫ mice, obvious genital bleeding was observed at any time between E7 to E9, and miscarriage occurred before E10.…”

Section: Discussionsupporting

confidence: 48%

Fibrinogen Stabilizes Placental-Maternal Attachment During Embryonic Development in the Mouse

Iwaki

Sandoval-Cooper

Paiva

et al. 2002

The American Journal of Pathology

View full text Add to dashboard Cite

Fibrinogen (Fg) is a 340-kd symmetrical heterodimeric protein consisting of three pairs of nonidentical polypeptide chains, and has an overall structure of (A␣/B␤/␥) 2 . This protein is the precursor of fibrin, formed during the hemostatic response. Three separate genes, FGA, FGB, and FGG, located on a 50-kb region of chromosome 4q28-q31, are translated in a coordinated fashion to code for the A␣-, B␤-, and ␥-chains, respectively, of Fg. 1 For its conversion into fibrin, thrombin first catalyzes release of fibrinopeptides A and B from the A␣ and B␤ chains, thus leading to exposure of polymerization sites that organize the initially formed fibrin monomers into a polymeric network of fibers that form the major protein component of the blood clot. This clot is ultimately covalently stabilized by crosslinking of specific ⑀-NH 2 groups of Lys and ␥-COOH groups of Glu residues of fibrin monomer, a process catalyzed by a transglutaminase, namely, activated Factor XIII (FXIIIa). 2

show abstract

Section: Discussionsupporting

confidence: 48%

Fibrinogen Stabilizes Placental-Maternal Attachment During Embryonic Development in the Mouse

Iwaki

Sandoval-Cooper

Paiva

et al. 2002

The American Journal of Pathology

View full text Add to dashboard Cite

show abstract

“…Factor replacement has been used to reduce the probability of miscarriage in women with deficiency of FXIII and fibrinogen [240,248,249]. However, there is currently no evidence for its role in women with other bleeding disorders.…”

Section: Other Gynaecological Problems In Women With Inherited Bleedimentioning

confidence: 99%

The obstetric and gynaecological management of women with inherited bleeding disorders – review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors’ Organization

et al. 2006

View full text Add to dashboard Cite

Summary. The gynaecological and obstetric management of women with inherited coagulation disorders requires close collaboration between obstetrician/ gynaecologists and haematologists. Ideally these women should be managed in a joint disciplinary clinic where expertise and facilities are available to provide comprehensive assessment of the bleeding disorder and a combined plan of management. The haematologist should arrange and interpret laboratory tests and make provision for appropriate replacement therapy. These guidelines have been provided for healthcare professionals for information and guidance and it is also intended that they are readily available for women with bleeding disorders.

show abstract

“…In the last 20 years, there have been several case reports and case series documenting the profoundly increased risk of miscarriage and placental abruption resulting in foetal loss or premature delivery in women with deficiency of fibrinogen [42][43][44][45][46][47][48][49][50][51], or factor XIII [52][53][54][55] but whether there is an increased risk of miscarriage in women with other bleeding disorders is not clear [18]. Clotting factor replace-ment is used to reduce the risk of miscarriage, foetal loss and premature delivery in women with deficiency of fibrinogen [43][44][45][47][48][49][50][51] and factor XIII [52][53][54][55], but whether any therapy is necessary or available to prevent miscarriage or foetal loss in women with other bleeding disorders has not been reported.…”

Section: Pregnancy and Childbirthmentioning

confidence: 99%

“…Clotting factor replace-ment is used to reduce the risk of miscarriage, foetal loss and premature delivery in women with deficiency of fibrinogen [43][44][45][47][48][49][50][51] and factor XIII [52][53][54][55], but whether any therapy is necessary or available to prevent miscarriage or foetal loss in women with other bleeding disorders has not been reported.…”

Section: Pregnancy and Childbirthmentioning

confidence: 99%

Women and bleeding disorders

James

2010

Haemophilia

View full text Add to dashboard Cite

Summary. While women are rarely affected by haemophilia, they are equally as likely as men to have other bleeding disorders. Menorrhagia, or heavy menstrual bleeding, is the most common symptom that they experience. Not only is menorrhagia more prevalent among women with bleeding disorders, but bleeding disorders are more prevalent among women with menorrhagia. Although menorrhagia is the most common reproductive tract manifestation of a bleeding disorder, it is not the only manifestation. Women with bleeding disorders appear to be at an increased risk of developing haemorrhagic ovarian cysts and possibly endometriosis. Women suspected of having a bleeding disorder or being a carrier of haemophilia should be offered diagnostic testing before getting pregnant to allow for appropriate preconception counselling and pregnancy management. During pregnancy, women with bleeding disorders may be at an increased risk of bleeding complications. At the time of childbirth, women with bleeding disorders appear to be more likely to experience postpartum haemorrhage, particularly delayed or secondary postpartum haemorrhage. As women with bleeding disorders grow older, they may be more likely to manifest gynaecological conditions which present with bleeding. Women with bleeding disorders are more likely to undergo a hysterectomy and are more likely to have the operation at a younger age. While women with bleeding disorders are at risk for the same obstetrical and gynaecological problems that affect all women, women with bleeding disorders are disproportionately affected by conditions that manifest with bleeding. Optimal management involves the combined expertise of haemostasis experts and obstetrician-gynaecologists.

show abstract

Congenital afibrinogenaemia and successful pregnancy outcome. Case report

Cited by 38 publications

References 11 publications

Fibrinogen Stabilizes Placental-Maternal Attachment During Embryonic Development in the Mouse

Fibrinogen Stabilizes Placental-Maternal Attachment During Embryonic Development in the Mouse

The obstetric and gynaecological management of women with inherited bleeding disorders – review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors’ Organization

Women and bleeding disorders

Contact Info

Product

Resources

About